Volume 5, Issue 14: Agents for the management of Pseudomonas aeruginosa infection
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 14)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Discuss optimal therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis
- Describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibrosis
- Evaluate the optimal choice of antibiotics to treat Pseudomonas-associated pulmonary exacerbations in patients with cystic fibrosis
Ottawa Hospital Research Institute
University of Ottawa
Dr. Shawn Aaron reports he has no relevant relationships with a commercial entity.
Dr. Shawn Aaron reports there will be discussions of off-label or unapproved uses including inhaled colistin, inhaled levofloxacin, inhaled ciprofloxacin, liposomal amikacin, doripenem, and sitafloxacin.
- 0.50 ANCC
- 0.50 Attendance